Dr. Reddy's 3QFY01: The Cheminor muscle - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy's 3QFY01: The Cheminor muscle

Jan 31, 2001

Dr. Reddy’s has reported a 45% growth in net profits, in the third quarter of the current year on the back of a 77% topline growth. However, these numbers are not comparable as the current year’s third quarter numbers include those of Cheminor Laboratories. Infact, on a consolidated basis the company’s topline has grown by 26% plus while the net profit’s have grown by 14% plus. The margin growth has been relatively slower primarily because of the increase of the contribution from bulk drugs. (Bulk drugs contribute around 51% of the combined company’s turnover.)

(Rs m) 3QFY00 3QFY01 Change
Sales 1,210 2,144 77.2%
Other Income 3 84 2706.7%
Expenditure 908 1,687 85.9%
Operating Profit (EBDIT) 303 457 50.9%
Operating Profit Margin (%) 25.0% 21.3%  
Interest 30 76  
Depreciation 44 102 130.5%
Profit before Tax 231 362 57.0%
Other Adjustments   -  
Tax 10 43 326.0%
Profit after Tax/(Loss) 221 320 44.8%
Net profit margin (%) 18.2% 14.9%  
Earnings per share* 27.96 40.47  

While the bulk actives business grew by 27% the generic sales in developed market took off in the third quarter of December 31, 2000. The finished dosages at Rs. 998 m contributed to 46% of revenues. Another significant development in the third quarter was the fact that the company’s anti-cancer compound DRF 1042 entered Phase I of clinical trials.

During the quarter all the company’s main brands Omez (anti–ulcer), Nise (anti–pain), Enam (cardiovascular) and Stamlo registered growth rates much higher than the rate of growth of overall pharmaceutical formulations. While the industry grew by 11%, Omez grew by 20%. Nise registered a growth of 17%, while Enam and Stamlo (including Stamlo Beta) grew by 29% and 26% respectively. The company also launched eight new brands, which catered to therapeutic areas such as anti–arthritis, anti–diabetes and cholesterol reducers.

The stock quotes at Rs 1,300 currently which implies an earnings multiple of 32 times 3QFY01 earnings.

Equitymaster requests your view! Post a comment on "Dr. Reddy's 3QFY01: The Cheminor muscle". Click here!

  

More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Don't Sell these Stocks if the Market Falls (Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 29, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS